GSDMD and rheumatoid arthritis: In RA patients, complement 1q (C1q) and PTX3 act synergistically to induce GSDMD-dependent pyroptosis in CD14+ monocytes, while promoting the release of inflammatory cytokines (tumor necrosis factor-α, IL-1β and IL-6).